Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 11/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24031269 | 0.75 | HSD17B10 (0.48) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL20536435 | 0.70 | HSD17B10 (0.43) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL30444035 | 0.70 | HSD17B10 (0.43) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL10650840 | 0.70 | HSD17B10 (0.52) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL473963 | 0.70 | TRPV4 (0.57) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL17672644 | 0.70 | HSD17B10 (0.52) | HSD17B10TTRESR1CA12CA1 | |
| SCHEMBL17672488 | 0.69 | CA9 (0.47) | HSD17B10TTRESR1CA12CA2 | |
| SCHEMBL17672490 | 0.68 | TSHR (0.53) | HSD17B10TTRCA12CA1CA2 | |
| SCHEMBL24258157 | 0.67 | APP (0.48) | HSD17B10ESR1CA12CA1CA2 | |
| SCHEMBL24258142 | 0.65 | CA12 (0.45) | HSD17B10ESR1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2021-06-24 | — | — | US | disclosed |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-27 | — | — | US | disclosed |
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | IL DONG PHARMACEUTICAL CO., LTD. (KR) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115349-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | HSD17B10 455/4885TTR 4266/4885ESR1 463/4885 |
| US-20210188790-A1 | ISOXAZOLE DERIVATIVES AS NUCLEAR RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H3, NR1H2 | HSD17B10 244/4885TTR 2448/4885ESR1 472/4885 |
| US-10988449-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | HSD17B10 455/4885TTR 4266/4885ESR1 463/4885 |
| US-11912674-B2 | Isoxazole derivatives as nuclear receptor agonists and uses thereof | NR1H4, NR1H3, NR1H2 | HSD17B10 244/4885TTR 2448/4885ESR1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.